Patent intelligence · US
US 10457745
Anti-complement C1s antibodies
Anti-complement C1s antibodies
Patent details — US 10457745
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 29, 2019
- Expiration
- Oct 24, 2039
- Applicant
- Bioverativ USA Inc.
- Claims
- 10
- CPC classes
- A61K, A61K2039/54, A61K2039/545, A61P
Quick answer
US 10457745 (Anti-complement C1s antibodies) is held by Bioverativ USA Inc.. Status: granted. Granted Oct 29, 2019. Expires Oct 24, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bioverativ USA Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2039/54, A61K2039/545, A61P, A61P13/12, A61P17/00
More from Bioverativ USA Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 10457745?
US 10457745 (Anti-complement C1s antibodies) is held by Bioverativ USA Inc.. Status: granted. Granted Oct 29, 2019. Expires Oct 24, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10457745?
Bioverativ USA Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 10457745 expire?
Our index shows an expiration date of Oct 24, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.